Different Doses Of Atorvastatin Improve The Forward Blood Flow In The No-reflow Rats Associated With Inflammation

Objective:Build acute myocardial ischemia/reperfusion model, administrate with different doses of atorvastatin priorly, observe the different doses of atorvastatin improving the forward blood flow in the no-reflow rats associated with inflammation.Method: Health male rats were randomly divided into four group, normal control group, sham group, acute ischemia/reperfusion group, large dose atorvastatin group and moderate dose atorvastatin group. Each group should be 6 successful model at least. We used Evans Blue staining, Thioflavin-S staining and TTC staining measuring the myocardial area size of risk,the myocardial area size of no-reflow and the myocardial area size of infarct. We researched the effection of atorvastatin on cadiac function in no-reflow phenomenon of the rats with acute myocardial ischemia/reperfusion with echocardiography evaluation and hemodynamics analysis measure.Result: After acute ischemia/reperfusion,the myocardial of rats appeared some size ofno-reflow and infarct. Atorvastatin could significantly reduce the myocardial area size of no-reflow and infarct (p>0.05). Echocardiography showed the reduction movement of some part left ventricular wall in myocardial ischemia/ reperfusion rats, but the structure and function of rat cadiac of each group had no obvious changs. Hemodynamics analysis proved that the maximum change rate of left ventricular pressure fall visible declined in the rats with acute myocardial ischemia/reperfusion(p>0.05). Atorvastatin had improve the maximum change rate of left ventricular pressure fall significantly(p>0.05). But there was no dose-dependently on the effect of cardiac function myocardial area size of no-reflow and infarct and in statistics (p<0.05).Conclusion:Atorvastatin could reduce the myocardial area size ofno-reflow and infarct,and improve the cardiac diastolic function of the rats with acute myocardial ischemia/reperfusion. There was a dose-dependent effect without statistical change. Objective: Build acute myocardial ischemia/reperfusion model, administrate with different doses of atorvastatin priorly, research the mechanism of research the different doses of atorvastatin improve the forward blood flow in the no-reflow rats associated with inflammation.Method: Store the myocardium andperipheral blood of each group in part one. We observe the myocardial change and the microthrombosis of myocardium with HE staining, MSB staining and Mason staining. The expression of fgl-2 was showed by immunohistochemistry staining of fgl-2 in myocardial microvascular.We used western blotting to detect fgl-2 in myocardium and peripheral blood. The expression of TNF-αwas detect by ELASA in peripheral blood.Result: After acute myocardial ischemia/ reperfusion, HE staining demonstrated the myocardial damage, cardiac cell apoptosis and structure disorder; MSB staining and Masson staining could display the microthrombosis in situ; The expression of fgl-2 was showed in the wall of myocardial microvascular by immunohistochemistry staining. There were moderate change in atorvastatin group. Meanwhile, western blotting measured the obvious expression of fgl-2 in myocardium and peripheral blood of rats with acute myocardial ischemia/reperfusion(p>0.05),and atorvastatin could reduce the expression of fgl-2 in myocardium and peripheral blood(p>0.05),. By ELISA test, The expression of TNF-αwas significant change in peripheral blood of rats with acute myocardial ischemia/reperfusion(p>0.05). Atorvastatin could reduce the expression of fgl-2 in myocardium and peripheral blood(p>0.05). But there was no dose-dependently on the effect of fgl-2 and TNF-αin statistics (p<0.05).Conclusion:Atorvastatin could decrease the expression of TNF-αand fgl-2 in myocardium and peripheral blood,then decline the tendency to generate microthrombosis in no-reflow phenomenon of the rats with acute myocardial ischemia/reperfusion.